The effect of HAART on humoral immune response in primary HIV-1 infected patients.

Claudia Pastori(Vita-Salute San Raffaele University), Lucia Lopalco(Vita-Salute San Raffaele University), Adriano Lazzarin(Vita-Salute San Raffaele University), Claudia Barassi(Vita-Salute San Raffaele University), Flavia Lillo(Vita-Salute San Raffaele University), Brunella Capiluppi(Vita-Salute San Raffaele University), Silvia Nozza(IRCCS Ospedale San Raffaele), Giuseppe Tambussi(San Raffaele University of Rome), Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Renato Longhi(Institute of Chemistry of Molecular Recognition)
PubMed
December 4, 2002
Cited by 4

Related Papers

Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Control of HIV despite the Discontinuation of Antiretroviral Therapy
|New England Journal of Medicine|1999|328